<DOC>
	<DOC>NCT00378508</DOC>
	<brief_summary>This is a randomized placebo controlled study to test whether a single 14 course of treatment with the anti-CD3 monoclonal antibody, hOKT3gamma1(Ala-Ala),Teplizumab will prevent the loss of insulin secretory capacity in individuals with Type 1 diabetes of 4 - 12 months duration since diagnosis.</brief_summary>
	<brief_title>Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes</brief_title>
	<detailed_description>The study design is a double blind placebo controlled trial that will enroll subjects between the ages of 8 - 30 who have had the diagnosis of Type 1 diabetes made 4 - 12 months prior to enrollment. A single 14 course of treatment with mAb hOKT3gamma1(Ala-Ala), Teplizumab will be given. The primary endpoint is the C-peptide response to a mixed meal at 12 months. A total of 60 subjects will be enrolled (30 in the drug treatment and 30 in the placebo groups) at 4 study sites: Yale University,the University of California at San Francisco, Children's Hospital of Philadelphia, and the Barbara Davis Diabetes Center.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>age 8 30, duration of diabetes 4 12 months, weight greater than 27.5 kg, stimulated Cpeptide &gt;= 0.2 pmol/ml asthma, history of hepatitis C, hepatitis B, HIV</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>immune therapy</keyword>
	<keyword>autoimmunity</keyword>
	<keyword>insulin secretion</keyword>
	<keyword>diabetes mellitus</keyword>
</DOC>